Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Knockdown of RPL34 markedly inhibited the proliferation, migration, and invasion, as well as prevented the epithelial-mesenchymal transition phenotype in glioma cells.
|
30216512 |
2019 |
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Our in vitro experiments suggested RPL34-AS1 inhibits esophageal cancer cell proliferation, migration and invasion through down-regulating RPL34 expression.
|
31574377 |
2019 |
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
The qRT-PCR and western blot were performed to measure RPL34 expression, CCK-8 and flow cytometry to observe cell growth and apoptosis, and wound healing and transwell to detect cell migration and invasion.
|
28697409 |
2017 |
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Knockdown of RPL34 efficiently inhibited esophageal cancer cell proliferation, migration, and invasion in vitro.
|
28109079 |
2017 |
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
This study aims to investigate the correlation of RPL34 with the cell growth and metastasis of oral squamous cell carcinoma (OSCC) as well as its clinical prognosis.
|
28697409 |
2017 |
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, our study revealed that RPL34 functions as an oncogene that modulates the proliferation and metastasis of esophageal cancer cells, in part, by the inactivation of the PI3K/Akt signaling pathway.
|
28109079 |
2017 |
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Clinically, our data indicate a positive association of RPL34 expression with tumor stage and metastasis in PCs.
|
27845896 |
2016 |
Secondary malignant neoplasm of lymph node
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In addition, esophageal cancer patients with Ⅲ-Ⅳ, T3-T4 or positive lymph node metastasis had lower RPL34-AS1expression levels than esophageal cancer patients with Ⅰ-Ⅱ, T1-T2 or negative lymph node metastasis, respectively.
|
31574377 |
2019 |
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Aberrant expression of RPL34 has been reported in several human malignancies.
|
28109079 |
2017 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Finally, knockdown of RPL34 attenuated tumor growth in nude mice.
|
28109079 |
2017 |
Secondary malignant neoplasm of lymph node
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The RPL34 expression was significantly correlated with differentiation degree, TNM stage and lymph node metastasis.
|
28697409 |
2017 |
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Clinically, our data indicate a positive association of RPL34 expression with tumor stage and metastasis in PCs.
|
27845896 |
2016 |
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
To examine the role of ribosomal protein L34 (RPL34) in cancer transformation, we assessed its expression in gastric cancer cell lines and found it highly expressed.
|
26323242 |
2015 |
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, RPL34 may serve as a potential therapeutic target for the treatment of glioma.
|
30216512 |
2019 |
Tumor Progression
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Ribosomal protein L34 (RPL34), belonging to the L34E family of ribosomal proteins, was reported to be dysregulated in several types of cancers and plays important roles in tumor progression.
|
30216512 |
2019 |
Mental Depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that ribosomal genes, particularly RPL17 and RPL34, can play integral roles in stress vulnerability and depression across nonclinical and clinical conditions.
|
30103068 |
2018 |
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that ribosomal genes, particularly RPL17 and RPL34, can play integral roles in stress vulnerability and depression across nonclinical and clinical conditions.
|
30103068 |
2018 |
Unipolar Depression
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the upregulation of RPL17 and RPL34 was most marked in DSM-IV major depressive disorder, followed by in bipolar disorder, and then in schizophrenia, suggesting some diagnostic specificity of these markers as well as their general roles in stress vulnerability.
|
30103068 |
2018 |
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These results suggest that ribosomal genes, particularly RPL17 and RPL34, can play integral roles in stress vulnerability and depression across nonclinical and clinical conditions.
|
30103068 |
2018 |
Major Depressive Disorder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the upregulation of RPL17 and RPL34 was most marked in DSM-IV major depressive disorder, followed by in bipolar disorder, and then in schizophrenia, suggesting some diagnostic specificity of these markers as well as their general roles in stress vulnerability.
|
30103068 |
2018 |
Esophageal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Knockdown of RPL34 efficiently inhibited esophageal cancer cell proliferation, migration, and invasion in vitro.
|
28109079 |
2017 |
Esophageal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Knockdown of RPL34 efficiently inhibited esophageal cancer cell proliferation, migration, and invasion in vitro.
|
28109079 |
2017 |
Malignant neoplasm of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Knockdown of RPL34 efficiently inhibited esophageal cancer cell proliferation, migration, and invasion in vitro.
|
28109079 |
2017 |
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These data indicate that over-expressed RPL34 may promote malignant proliferation of NSCLC cells, thus playing an important role in development and progress of NSCLC.
|
26526135 |
2016 |
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that RPL34 plays an important role in the proliferation of osteosarcoma cells.
|
27883047 |
2016 |